With the increase in obesity throughout the world, liver disease and nonalcoholic steatohepatitis (NASH)-related cancers are also increasing. Treatments are urgently needed to prevent the progression from nonalcoholic fatty liver disease (NAFLD) to NASH and hepatocellular carcinoma (HCC) via steatosis and fibrosis. Spectrin Bio aims to apply our siRNA therapy to treat obesity-associated nonalcoholic steatohepatitis (NASH) and liver cancer Our drug target is β-Spectrin (SPTBN1), a key player in both steatosis and fibrosis. Preclinical findings in mice (in vivo) and human 3D culture NASH model system have shown success in reducing body fat and lowering blood triacyl glycerol leves. Critically, siRNA therapies are already approved for diseases of the liver, blazing a trail for navigating regulatory approval.